Comparative Pharmacology
Head-to-head clinical analysis: OXTELLAR XR versus OXYMORPHONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTELLAR XR versus OXYMORPHONE HYDROCHLORIDE.
OXTELLAR XR vs OXYMORPHONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.
Oxymorphone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception and response. It also has affinity for kappa and delta opioid receptors.
Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.
Initial: 1 mg IV/IM every 3-4 hours as needed for moderate to severe pain; titrate to effect. For patient-controlled analgesia (PCA), 0.5 mg IV loading dose, then 0.25-0.5 mg every 6-15 minutes with lockout. Rectal suppository: 5 mg every 4-6 hours.
None Documented
None Documented
Terminal half-life approximately 20-30 hours in adults; after multiple doses, effective half-life is about 24 hours, allowing once-daily dosing. Steady state reached in 4-5 days.
Terminal elimination half-life: 7-9 hours (range 4-12 h in elderly/renal impairment). Clinically, steady-state achieved within 24-36 hours.
Primarily renal (70-80% as unchanged drug and metabolites) and fecal (20-30% via biliary excretion).
Primarily renal (90% as parent drug and metabolites); <1% fecal. Unchanged oxymorphone accounts for ~30% of urinary recovery.
Category C
Category C
Opioid Analgesic
Opioid Analgesic